Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Szubert

Showing results (31-40 of 46) with videos related to

Pageof 5
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 5, 2013
Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX StudyAndy C Rawstron, J Anthony Child, Ruth M de Tute, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2014
Reply to M. Roschewski et alAndy C Rawstron, J Anthony Child, Ruth M de Tute, et al.
Blood|October 25, 2011
The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysisGareth J Morgan, Walter M Gregory, Faith E Davies, et al.
Haematologica|November 8, 2011
Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial resultsGareth J Morgan, Faith E Davies, Walter M Gregory, et al.
Lancet (London, England)|December 7, 2010
First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trialGareth J Morgan, Faith E Davies, Walter M Gregory, et al.
Blood|June 10, 2011
Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantationGareth J Morgan, Faith E Davies, Walter M Gregory, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 14, 2023
First Pharmacokinetic Data of Tenofovir Alafenamide Fumarate and Tenofovir With Dolutegravir or Boosted Protease Inhibitors in African Children: A Substudy of the CHAPAS-4 TrialHylke Waalewijn, Alexander J Szubert, Roeland E Wasmann, et al.
The Lancet. Oncology|July 21, 2011
Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trialGareth J Morgan, J Anthony Child, Walter M Gregory, et al.
The New England Journal of Medicine|July 21, 2017
Enhanced Prophylaxis plus Antiretroviral Therapy for Advanced HIV Infection in AfricaJames Hakim, Victor Musiime, Alex J Szubert, et al.
British Journal of Haematology|March 29, 2014
Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma IX Study resultsGraham H Jackson, Gareth J Morgan, Faith E Davies, et al.
Pageof 5

Showing results (31-40 of 46) with videos related to

Sort By:
Pageof 5
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 5, 2013
Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX StudyAndy C Rawstron, J Anthony Child, Ruth M de Tute, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2014
Reply to M. Roschewski et alAndy C Rawstron, J Anthony Child, Ruth M de Tute, et al.
Blood|October 25, 2011
The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysisGareth J Morgan, Walter M Gregory, Faith E Davies, et al.
Haematologica|November 8, 2011
Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial resultsGareth J Morgan, Faith E Davies, Walter M Gregory, et al.
Lancet (London, England)|December 7, 2010
First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trialGareth J Morgan, Faith E Davies, Walter M Gregory, et al.
Blood|June 10, 2011
Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantationGareth J Morgan, Faith E Davies, Walter M Gregory, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 14, 2023
First Pharmacokinetic Data of Tenofovir Alafenamide Fumarate and Tenofovir With Dolutegravir or Boosted Protease Inhibitors in African Children: A Substudy of the CHAPAS-4 TrialHylke Waalewijn, Alexander J Szubert, Roeland E Wasmann, et al.
The Lancet. Oncology|July 21, 2011
Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trialGareth J Morgan, J Anthony Child, Walter M Gregory, et al.
The New England Journal of Medicine|July 21, 2017
Enhanced Prophylaxis plus Antiretroviral Therapy for Advanced HIV Infection in AfricaJames Hakim, Victor Musiime, Alex J Szubert, et al.
British Journal of Haematology|March 29, 2014
Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma IX Study resultsGraham H Jackson, Gareth J Morgan, Faith E Davies, et al.
Pageof 5